ES2135343A1 - Mejoras en la profilaxis del cancer de mama, o relacionadas con esta. - Google Patents

Mejoras en la profilaxis del cancer de mama, o relacionadas con esta.

Info

Publication number
ES2135343A1
ES2135343A1 ES09702225A ES9702225A ES2135343A1 ES 2135343 A1 ES2135343 A1 ES 2135343A1 ES 09702225 A ES09702225 A ES 09702225A ES 9702225 A ES9702225 A ES 9702225A ES 2135343 A1 ES2135343 A1 ES 2135343A1
Authority
ES
Spain
Prior art keywords
raloxifene
prophylaxis
breast cancer
administration
relating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
ES09702225A
Other languages
English (en)
Inventor
Frederic Jay Cohen
Joan Ellen Glusman
Ronald Keith Knickerbocker
Nikolaus Thomas Nickelsen
Teri Janine Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268608&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2135343(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9624800.0A external-priority patent/GB9624800D0/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of ES2135343A1 publication Critical patent/ES2135343A1/es
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Abstract

Uso del raloxifeno o sus sales en la preparación de un medicamento para la profilaxis del cáncer de mama. La profilaxis del cáncer de mama en una mujer postmenopáusica, administrando a dicha mujer raloxifeno, o una de sus sales farmacéuticamente aceptables, en una cantidad de aproximadamente 60 a aproximadamente 120 mg por día.
ES09702225A 1996-10-30 1997-10-28 Mejoras en la profilaxis del cancer de mama, o relacionadas con esta. Withdrawn ES2135343A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2985096P 1996-10-30 1996-10-30
GBGB9624800.0A GB9624800D0 (en) 1996-11-29 1996-11-29 Methods of preventing breast cancer
US4026097P 1997-03-10 1997-03-10

Publications (1)

Publication Number Publication Date
ES2135343A1 true ES2135343A1 (es) 1999-10-16

Family

ID=27268608

Family Applications (4)

Application Number Title Priority Date Filing Date
ES09702225A Withdrawn ES2135343A1 (es) 1996-10-30 1997-10-28 Mejoras en la profilaxis del cancer de mama, o relacionadas con esta.
ES009702224A Expired - Fee Related ES2135342B1 (es) 1996-10-30 1997-10-28 Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
ES97308588T Expired - Lifetime ES2197312T3 (es) 1996-10-30 1997-10-29 Mejoras en o en relacion con la profilaxis del cancer de mama por administracion de raloxifeno.
ES03102726T Expired - Lifetime ES2271476T3 (es) 1996-10-30 1997-10-29 Procedimientos de prevencion de cancer de mama por administracion de raloxifeno.

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES009702224A Expired - Fee Related ES2135342B1 (es) 1996-10-30 1997-10-28 Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
ES97308588T Expired - Lifetime ES2197312T3 (es) 1996-10-30 1997-10-29 Mejoras en o en relacion con la profilaxis del cancer de mama por administracion de raloxifeno.
ES03102726T Expired - Lifetime ES2271476T3 (es) 1996-10-30 1997-10-29 Procedimientos de prevencion de cancer de mama por administracion de raloxifeno.

Country Status (44)

Country Link
US (2) US6303634B1 (es)
EP (3) EP0839533A1 (es)
JP (2) JPH10147530A (es)
CN (2) CN1182591A (es)
AP (1) AP971A (es)
AR (2) AR010538A1 (es)
AT (2) ATE239475T1 (es)
AU (3) AU5005197A (es)
BE (2) BE1011381A5 (es)
BG (1) BG63841B1 (es)
BR (1) BR9712703A (es)
CA (2) CA2219070C (es)
CH (2) CH691847A5 (es)
CZ (2) CZ300261B6 (es)
DE (2) DE69721692T2 (es)
DK (2) DK0839532T3 (es)
EA (2) EA006083B1 (es)
EE (1) EE03663B1 (es)
ES (4) ES2135343A1 (es)
FR (2) FR2756490B1 (es)
GB (3) GB2318734B (es)
GE (1) GEP20032910B (es)
GR (2) GR970100409A (es)
HK (1) HK1010495A1 (es)
HU (2) HUP9701777A3 (es)
IE (2) IE970773A1 (es)
IL (2) IL122026A0 (es)
IS (1) IS5035A (es)
IT (2) ITMI972434A1 (es)
LU (2) LU90158B1 (es)
LV (1) LV12353B (es)
MY (1) MY121623A (es)
NL (2) NL1007387C2 (es)
NO (2) NO974973D0 (es)
NZ (1) NZ329042A (es)
PT (2) PT1369115E (es)
RO (1) RO120813B1 (es)
SG (2) SG83672A1 (es)
SI (3) SI0839532T1 (es)
SK (1) SK287047B6 (es)
TR (1) TR199900951T2 (es)
UA (1) UA46762C2 (es)
WO (2) WO1998018325A1 (es)
YU (1) YU42397A (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
FI982733A (fi) 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
EP1395563B1 (en) 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US6962928B2 (en) 2001-05-22 2005-11-08 Eli Lilly And Company Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis
US20040225200A1 (en) * 2003-05-09 2004-11-11 Edmundson Catherine M. System and method of analyzing the health of a population
GR1005694B (el) * 2005-06-08 2007-10-22 Αλεξης Μιχαηλ Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102973573B (zh) * 2012-11-28 2015-04-08 玉林师范学院 一种人乳腺癌细胞抑制剂及制备方法
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
CN116650484A (zh) * 2023-05-11 2023-08-29 南通大学 一种乳腺癌相关蛋白的抑制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0680758A1 (en) * 1994-05-05 1995-11-08 Eli Lilly And Company Pharmaceutical compositions containing tamoxifen or analogs and raloxifene or analogs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
CZ253694A3 (en) * 1993-10-15 1995-05-17 Lilly Co Eli Pharmaceutical preparation for treating resistant neoplasms
CA2143263C (en) * 1994-03-02 2002-01-08 Kerry John Hartauer Orally administrable raloxifene formulations
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
US5821254A (en) 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
CZ300341B6 (cs) * 1996-03-26 2009-04-22 Eli Lilly And Company Farmaceutická kompozice obsahující raloxifen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0680758A1 (en) * 1994-05-05 1995-11-08 Eli Lilly And Company Pharmaceutical compositions containing tamoxifen or analogs and raloxifene or analogs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JORDAN et al. Alternate antiestrogens and approaches to the prevention of breast cancer, Journal of Biochemistry, Vol. 58, no 522, 51-57 (1995), resumen; paginas 54,55; figura 3. *
M.A. ANZANO et al. Chemoprevention of Mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid, Journal of the National Cancer Institute, Vol. 88, no 2, Enero 1996, paginas 123-125. *

Also Published As

Publication number Publication date
AR010538A1 (es) 2000-06-28
CN1182590A (zh) 1998-05-27
IT1298470B1 (it) 2000-01-10
CA2219070C (en) 2007-12-18
IL122025A (en) 2003-01-12
JPH10147530A (ja) 1998-06-02
DE69721692T2 (de) 2004-03-25
FR2755014B1 (fr) 1999-02-05
TR199900951T2 (xx) 1999-07-21
AU4364897A (en) 1998-05-07
CZ300261B6 (cs) 2009-04-01
EP1369115A1 (en) 2003-12-10
HUP9701778A2 (hu) 1999-01-28
NL1007386C2 (nl) 1998-05-14
ATE338551T1 (de) 2006-09-15
LU90158B1 (fr) 1998-06-02
MX9708340A (es) 1998-08-30
BG63841B1 (bg) 2003-03-31
NO322468B1 (no) 2006-10-09
LV12353A (lv) 1999-10-20
SK287047B6 (sk) 2009-10-07
CZ341297A3 (cs) 1998-05-13
BE1011381A5 (fr) 1999-08-03
AP971A (en) 2001-05-30
NO974972L (no) 1998-05-04
IE970773A1 (en) 2000-02-09
DE69721692D1 (de) 2003-06-12
LV12353B (en) 2000-02-20
US20020019418A1 (en) 2002-02-14
ATE239475T1 (de) 2003-05-15
ES2135342A1 (es) 1999-10-16
SI0839532T1 (en) 2003-10-31
YU42397A (sh) 2000-10-30
GEP20032910B (en) 2003-03-25
EA006083B1 (ru) 2005-08-25
GB9722796D0 (en) 1997-12-24
PT1369115E (pt) 2006-12-29
EE9900162A (et) 1999-12-15
EP0839532B1 (en) 2003-05-07
CN1182591A (zh) 1998-05-27
NZ329042A (en) 1999-08-30
AR013864A1 (es) 2001-01-31
DK1369115T3 (da) 2007-01-02
SI1369115T1 (sl) 2006-12-31
SG83672A1 (en) 2001-10-16
HK1010495A1 (en) 1999-06-25
US6303634B1 (en) 2001-10-16
ITMI972433A1 (it) 1999-04-29
SG72765A1 (en) 2000-05-23
NO974973D0 (no) 1997-10-28
GB2318733A (en) 1998-05-06
UA46762C2 (uk) 2002-06-17
ES2197312T3 (es) 2004-01-01
DK0839532T3 (da) 2003-08-25
MY121623A (en) 2006-02-28
JPH10147529A (ja) 1998-06-02
BR9712703A (pt) 1999-10-26
CA2219377A1 (en) 1998-04-30
LU90157B1 (fr) 1998-06-02
AU4364797A (en) 1998-05-07
EA200100716A1 (ru) 2002-06-27
EP1369115B1 (en) 2006-09-06
IS5035A (is) 1999-04-27
EA002054B1 (ru) 2001-12-24
DE69736644D1 (de) 2006-10-19
EP0839532A1 (en) 1998-05-06
EE03663B1 (et) 2002-04-15
CH693820A5 (fr) 2004-02-27
GR970100409A (el) 1998-06-30
BG103369A (en) 2000-05-31
IL122026A0 (en) 1998-03-10
AU5005697A (en) 1998-05-22
WO1998018325A1 (en) 1998-05-07
MX9708341A (es) 1998-08-30
RO120813B1 (ro) 2006-08-30
CH691847A5 (fr) 2001-11-15
HUP9701778A3 (en) 1999-06-28
EA199900431A1 (ru) 1999-10-28
IE970772A1 (en) 2000-02-09
NL1007387C2 (nl) 1998-05-14
HU9701777D0 (en) 1997-12-29
HU9701778D0 (en) 1997-12-29
ES2135342B1 (es) 2000-05-16
BE1011382A5 (fr) 1999-08-03
WO1998018449A1 (en) 1998-05-07
PT839532E (pt) 2003-09-30
FR2756490B1 (fr) 2003-06-20
IL122025A0 (en) 1998-03-10
GR970100408A (el) 1998-06-30
EP0839533A1 (en) 1998-05-06
GB9722801D0 (en) 1997-12-24
GB2318734B (en) 1999-12-01
ES2271476T3 (es) 2007-04-16
AU731388B2 (en) 2001-03-29
AP9901494A0 (en) 1999-03-31
DE69736644T2 (de) 2007-10-25
FR2756490A1 (fr) 1998-06-05
ITMI972434A1 (it) 1999-04-29
GB2318734A (en) 1998-05-06
NO974972D0 (no) 1997-10-28
HUP9701777A3 (en) 1999-07-28
GB9911557D0 (en) 1999-07-21
FR2755014A1 (fr) 1998-04-30
AU5005197A (en) 1998-05-22
HUP9701777A2 (hu) 1999-06-28
SK55999A3 (en) 2000-06-12
SI20107A (sl) 2000-06-30
CZ341197A3 (cs) 1998-05-13
GR1003189B (el) 1999-09-01
CA2219070A1 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
ES2135343A1 (es) Mejoras en la profilaxis del cancer de mama, o relacionadas con esta.
SG45315A1 (en) Improvements in or relating to benzothiopenes
TW271395B (es)
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
BG103882A (en) Voriconazol-containing pharmaceutical compositions
ES2087237T3 (es) Progestogeno como unico contraceptivo.
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
PL310159A1 (en) Cylofulvenic analogues as antineoplastic agents
YU53402A (sh) Preparat
MX9602442A (es) Un tratamiento con fluoroquinolona a dosis unica elevada.
BG101875A (en) New cryptoficins and method for their preparation
BG105197A (en) Polymorph form of a medicament
EP0973518A4 (en) SEMI-SYNTHETIC PROCESSES FOR THE PREPARATION OF DIDEMNINE ANALOGS
JPH0784481B1 (es)
IL100458A0 (en) Pharmaceutical compositions containing antagonists of the quisqualate receptor
IL101163A (en) Use of flunarizine in the preparation of medicaments for treating neoplastic diseases
DE3473826D1 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
NZ336321A (en) Use of benzothiophene (raloxifene) for treating breast cancer
DE69614552T2 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
GB8908906D0 (en) Therapeutic compounds,compositions & uses thereof
FR2412306A1 (fr) Systeme de bras pour fauteuils de traitement, notamment pour fauteuils dentaires
MX9707735A (es) Nuevo uso de (s)-adenosil-l-metionina (same).
UA30250A (uk) Антиоксидантний засіб
MX9709683A (es) Uso de derivados de vitamina d4 para tratamiento contra el cancer.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19991016

Kind code of ref document: A1

Effective date: 19991016

FA2A Application withdrawn

Effective date: 19991223